ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

A Preview of ASH’s Venous Thromboembolism Clinical Practice Guidelines

In November 2015, the American Society of Hematology (ASH) and the McMaster University GRADE Center announced a collaboration to develop clinical practice guidelines on...

Newly Approved Drugs for AML: How to Use Them in Practice

In 2017, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of hematologic malignancies, including four for acute myeloid leukemia...

Preliminary Results Show Flotetuzumab Well-Tolerated and Effective in Relapsed/Refractory AML and MDS

In early results from a phase I trial presented at the 2017 ASH Annual Meeting, researchers reported that the bispecific antibody flotetuzumab demonstrated anti-leukemic...

Examining the Risk of Cardiovascular Disease–Related Mortality in Patients With and MDS/CMML

Patients with chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) have a higher risk of cardiovascular disease (CVD)–related mortality and cerebrovascular accident (CVA)–related mortality,...

Feeding the Fire: CHIP and Inflammation

Clonal hematopoiesis of indeterminate potential (CHIP), known as a “premalignant” state in the blood critical to the development of blood cancer, increases in frequency...

Treating MRD With Azacitidine in Patients With High-Risk AML and MDS

For 58 percent of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) at high risk for relapse, treatment of minimal residual disease...

Idasanutlin Well Tolerated in Patients With Polycythemia Vera and Essential Thrombocythemia

The MDM2 antagonist idasanutlin was well tolerated and demonstrated “clear clinical activity” in patients with polycythemia vera (PV) and essential thrombocythemia (ET) that was...

Haplo-HCT From Older Donors Associated With Worse Outcomes in Acute Leukemias

The use of haploidentical (haplo) related donors has made it possible for patients with leukemia who lack a human leukocyte antigen (HLA)–matched donor to...

Combining Recombinant Human Thrombopoietin With Corticosteroids in Immune Thrombocytopenia

Corticosteroids are the guideline-recommended firstline therapy for adult patients with immune thrombocytopenia (ITP), but a recent clinical trial suggests that regulating thrombopoiesis with recombinant...

Older Patients Underrepresented in Trials of Hematologic Malignancy Treatments

People over the age of 65 represent the majority of those diagnosed with hematologic malignancies, but they account for only about one-third of patients...
Advertisement

Current Issue

February 2018 Volume 4, Issue 3

This issue features a conversation with National Cancer Institute Director Norman “Ned” Sharpless, MD, a look at the prevalence and controversial nature of academic-industry partnerships, and more.